Adalimumab is a monoclonal antibody used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohns disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. It provides relief from swelling, pain, and redness associated with various disorders and improves physical function.
A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response.
Adalimumab is a disease modifying antirheumatic drug (DMARD) and monoclonal antibody that works by inactivating tumor necrosis factor alpha (TNF alfa). It is on the World Health Organizations List of Essential Medicines.
